Matthew R. Patterson, President & CEO at Audentes Therapeutics, Inc. (BOLD), sold 700 shares at $30.01 ($21K) on 2018-04-02, disclosed to the SEC on 2018-04-04.
Scheduled sale ($21k) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BOLD | SELL | 2019-02-27 | $630K | — | Filing → |
| BOLD | SELL | 2018-10-02 | $1.6M | — | Filing → |
| BOLD | SELL | 2018-09-20 | $518K | — | Filing → |